A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin

NCT06257966 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

Type2 Diabetes Mellitus

Interventions

DRUG: Exendin-4 Fc fusion protein injection(1.2mg）
DRUG: Exendin-4 Fc fusion protein injection（2.4mg）
DRUG: Dulaglutide
DRUG: Metformin

Sponsor

Beijing Dongfang Biotech Co., Ltd.